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Abstract. Background: In boron neutron capture therapy, blood
boron concentration is the key factor to calculate radiation dose,
however, blood sampling is difficult during neutron irradiation.
Materials and Methods: The prediction of blood boron
concentrations for BNCT treatment planning has been
prospectively investigated using patient data obtained at first
craniotomy after the infusion of a low dose of sodium
undecahydroclosododecaborate. Results: The boron biodistribution
data showed a biexponential pharmacokinetic profile. If the final
boron concentration at 6 or 9 hours after the end of the infusion is
within the 95% confidence interval of the prediction, direct
prediction from biexponential fit will reduce the error of blood
boron concentrations during irradiation to around 6%.
Conclusion: Actual boron concentrations during BNCT were
reasonably and accurately predictable from the test data.  
Glioblastoma is one of the most difficult malignant brain
tumors to treat. Although many researchers have attempted
different therapeutic modalities for malignant brain tumors,
the prognosis for patients with glioblastoma is still extremely
poor (1, 2). Boron neutron capture therapy (BNCT) is an
experimental radiation therapy with the major target being
glioblastoma (3, 4). In this treatment, selective accumulation
of the boron compound in tumor cells along with sufficient
thermal neutron irradiation are the key factors to the
delivery of an effective dose to the tumor cells. Clinical
trials of BNCT for patients with glioblastoma are presently
in progress, and many reports indicate the need for further
clinical trials of BNCT (5-11). At present, nuclear reactors
constitute the only source that can provide enough neutron
flux for BNCT.
At the Brookhaven National Laboratory, BNCT
irradiation is interrupted transiently at approximately the
mid-point of irradiation and blood samples taken. The
average blood boron concentration during BNCT is
calculated by linear extrapolation of the boron
concentrations obtained from blood samples collected at the
start, in the middle, and at the end of BNCT irradiation (7,
8). In Japan, venous blood is sampled before and after the
irradiation (10). The interruption of irradiation may be
time-consuming and costly. Moreover, it may make it
difficult to accurately calculate neutron fluence and simple
linear extrapolation of the boron concentrations might not
represent the exact boron dynamics.
In the Harvard-MIT clinical BNCT trial, blood samples
were drawn from the long central venous line during
neutron irradiation (12). Sampling blood from the long
central venous line is not easy because of the risk of
coagulation in the line, which might cause distal embolism.
In order to prevent blood from coagulating in the long
central venous line, the researchers used heparin in the
venous catheter. This clinical BNCT trial for patients with
brain tumors did not include a craniotomy during the
neutron irradiation, so it is possible that the local use of
heparin did not constitute any risk. The protocol at the
University of Tsukuba, Japan, and the Japan Atomic Energy
Research Institute (JAERI) involves the intra-operative use
of thermal neutron irradiation. Thus, even if the amount of
heparin used was small, the risk of hemorrhagic
complications should be taken into consideration.  
Nine patients with either glioblastoma or anaplastic
astrocytoma have already been treated in this study using
BNCT. In the protocol, each patient was first subjected to
an open craniotomy to remove as much of the tumor as
possible and to establish the pathological diagnosis.  After
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the tumor was pathologically diagnosed as glioblastoma or
anaplastic astrocytoma, the patient was considered eligible
for the BNCT protocol. Just prior to the BNCT irradiation
procedure, all the patients were placed under general
anesthesia for a second open craniotomy in the operating
room at JAERI. Patients were transported to a neutron
irradiation room that was tightly sealed and had a full life
monitoring system (5). Neutron irradiation usually lasted for
2 hours and, during this time, general anesthesia and life
monitoring were maintained from outside the irradiation
room. The irradiation time was determined by the boron
concentration in the venous blood drawn from the patient
just prior to neutron irradiation and by the neutron fluence
measured using activation analysis of gold wires that were
drawn from the irradiated area during neutron irradiation. 
During neutron irradiation, it was difficult to measure boron
concentration in the blood because the patient was in the
irradiation room and entry was not possible for blood sampling.
Therefore, we took a blood sample just prior to the neutron
irradiation and measured the blood boron concentration by
prompt gamma ray analysis (PGA). If the decline of the blood
boron concentration during treatment could be predicted prior
to neutron irradiation, we would be able to set the irradiation
time and doses more effectively.  Based on the data collected
from these patients, we prospectively investigated boron
pharmacokinetics in a candidate for BNCT at the first
craniotomy after infusion of a low dose of boron and analyzed
the possibility of predicting the final boron concentration in
blood at the time of the actual BNCT procedure.
Materials and Methods
Two patients were treated with BNCT at the Japan Research
Reactor 2(JRR2) in 1995/1996, and 7 at the Japan Research
Reactor 4(JRR4) in 1999-2001. Of these 9 patients, seven were
investigated in this study. The other 2 patients were excluded
because the first operation had been performed at other
institutions. The details of the patients are summarized in Table I.
All patients had normal renal function.  
Sodium undecahydroclosododecaborate (BSH) was purchased
from Boron Biologicals Inc. (Mt Airy, NC, USA), and Katchem Ltd.
(Praha, Czech Republic). According to the certificate of analysis
provided from Boron Biologicals Inc. and the Institute of Inorganic
Chemistry, Academy of Sciences of the Czech Republic, B10
enrichment was 92.0% and 99.7%, respectively. One gram of BSH
dissolved in 100 ml physiological saline was infused over 1 hour at 12
hours before the first surgery in the seven patients. Of the 100ml, an
aliquot of 2.5ml was reserved and used for a boron concentration
check in four cases. Venous blood was sampled 1, 3, 6, 9 and 12 hours
after the infusion in all cases and 24 hours in the 5 most recent cases.
As for case 1, we failed to obtain the data for the 9-hour time-point
after the infusion. At the time of the first operation, tumor tissue was
assayed for the boron concentration.  Boron concentrations in the
BSH solution, blood and tumor were examined using PGA or
inductively coupled plasma atomic emission spectroscopy (ICP-AES).
In this study we used only PGA data, because we believed PGA data
were more reliable than ICP-AES data which do not consider B10
enrichment of the boron compounds. All PGA data presented in this
paper are the mean value of several measurements of each sample.
All boron concentration data in blood were corrected using their
respective B10 enrichment calculated as the ratio of the actual and
expected boron concentrations.
BNCT was scheduled for about 1 month after the first
operation. The amount of infused BSH was determined based on
the dose of 100 mg of BSH/ kg body weight; thus 5g of BSH was
infused in all cases, except for case 5 where 8g of BSH was infused,
12 hours prior to BNCT. BSH was dissolved in 500 ml physiological
saline and infused over 1 hour. Of the 500 ml solution, an aliquot
of 2.5 ml was reserved and used for the boron concentration check,
except in 2 cases. Venous blood was sampled 1, 3, 6, 9 and 24 hours
after the end of the infusion and just before and after neutron
irradiation. Boron concentrations in venous blood were examined
using PGA and ICP-AES.  
All these procedures complied with the principles laid down in
the Declaration of Helsinki, and were approved by the Ethical
Committee of the University of Tsukuba and JAERI. A written
informed consent was obtained from all the patients and their
family in this study.  
To compare the data from test dose infusion and final dose
infusion, the test data were adjusted by simple multiplication.  If
the final dose of BSH was 5g, the figure from the test dose infusion
was multiplied by 5, assuming pharmacological dose vs. blood
concentration linearity. Four-parameter biexponential equations
were fitted using the least squares fit through points. This
regression analysis was carried out using Sigma Plot 2000 software
(SPSS Science, Chicago, IL, USA). The errors between real and
predicted values of blood boron concentration were evaluated. 
Results
Biexponential equation. Each patient showed a biexponential
blood clearance pharmacokinetic profile composed of an
initial rapid decline followed by a slow wash out (Figure 1).
The correlation indexes between the original data and the
fitted curves were >0.99 in all cases. From this biexponential
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Table I. Details of patients 
No. Age/Sex Histology BNCT Test Final 
dose(g)
dose(g)
1 45/M Glioblastoma JRR2 1 5
2 55/F Glioblastoma JRR4 1 5
3 48/F Glioblastoma JRR4 1 5
4 66/M Anaplastic astrocytoma JRR4 1 5
5 38/F Glioblastoma JRR4 1 8
6 64/F Glioblastoma JRR4 1 5
7 58/F Anaplastic astrocytoma JRR4 1 5
BNCT: boron neutron capture therapy
JRR: Japan Research Reactor
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Figure 1. The predicted and actual blood concentration of boron for each case.
equation, the 95% confidence intervals of the prediction
were calculated. Most final data of boron concentration
between 1 and 9 hours after the end of infusion were within
the 95% confidence interval of the prediction.  However, the
final data of boron concentrations of case 4 between 6 and 9
hours after the end of the infusion, and those of case 5
between 3 and 9 hours after the end of the infusion were
outside the 95% confidence interval of the prediction.    
Errors of predicted values. In our protocol, neutron
irradiation is carried out about 12 hours after the end of
BSH infusion. This time window was selected because the
highest tumor-to-blood ratios are obtained at this time-point
(13, 14), therefore boron concentrations within this time
period should be predicted accurately. Because the data
from the test dose infusion can be used to predict the boron
concentration during neutron irradiation, these data were
used to evaluate the errors in predicting the final boron
concentrations.  
The mean and median error of the blood boron
concentrations determined between 10 and 14 hours after
the BSH infusion were 15.77 and 11.76%. Errors of more
than 20% were observed only in Cases 4 and 5. In these 2
cases the final boron concentrations at 6 and 9 hours after
the end of the infusion were out of the 95% confidence
interval of the prediction. The mean and median error of
the blood boron concentrations determined between 10 and
14 hours after the BSH infusion in the other five cases were
8.54 and 6.38%.  
In order to reduce the error of prediction, we attempted
a proportional adjustment of the predicted value to fit the
final value by multiplying the ratio of the predicted and final
values at the 9-hour determination point. After this
adjustment, the mean and median error of the blood boron
concentrations determined between 10 and 14 hours after
the BSH infusion were 10.50 and 11.54% for all cases, and
17.73 and 11.99% for case 4 and case 5.
From these results, the following strategies are
recommended to predict boron concentration in blood. If the
final boron concentration at 6 or 9 hours after the end of the
infusion is within the 95% confidence interval of the
prediction, direct prediction from biexponential fit will bring
the error to around 6%. If the final boron concentration at 6
or 9 hours after the end of the infusion is out of the 95%
confidence interval of the prediction, adjustment will decrease
the error and the expected error will be between 10 to 17%.
Following is an illustrative case report showing that our
prediction method using test infusion data was useful to
determine irradiation time and doses. We usually set the
maximum reactor power to 2MW. Case 4 showed a
relatively slow wash out of BSH in a test biodistribution
study, even though this patient had normal renal function.
We therefore decreased the maximum reactor power from
the usual 2MW to 1.5MW. As a result, the neutron flux on
the brain surface of this patient was 1.84E9 cm-2sec-1. The
mean brain surface neutron flux of the other 4 patients who
were irradiated at 2MW atomic reactor power in JRR4 was
2.38E9±2.33E8 cm-2sec-1. Using this low neutron flux, we
could safely complete the BNCT procedure for this patient
with a relatively high boron concentration in blood, in the
usual irradiation time.
Tumor boron concentration and dose calculation. Several
tumor samples were taken to determine the boron
concentration during the first operation. Usually the boron
concentration in the tumor varies because of tumor
heterogeneity. There are many discussions regarding tumor
sampling and tumor dose calculations. We calculated the
10B(n,·)7Li, 14N(n,p)14C, fast neutron and gamma dose for
both normal tissue and tumor in every case; however, these
values depend, in part, on the methods of measurement and
calculation. Because tumor boron concentration and dose
calculation are beyond the scope of the present study, we
have only discussed blood boron concentration in this paper.
Discussion
In our study, the single parameter biexponential equations
and the approximate curves fit well for all data. The
correlation indexes between the original data and the
approximate curves were greater than 0.99 in all cases.
These findings suggest that the blood clearance of BSH is
biexponential and biphasic, and that actual measurement at
some time-points is sufficient for drawing these curves. All
previous reports have found that the blood clearance of
BSH is biphasic (11, 13-19) or triphasic (20, 21). 
Gabel et al. reported that the blood boron concentration
showed a linear correlation with the BSH dose infused (16).
The present results support their findings. Using the
proposed prediction method, the median error of boron
concentration was 11.76% up to 14 hours after the BSH
infusion. Thus, we were able to predict the boron
concentration after the infusion of a full dose of BSH from
the boron concentrations measured after infusion of 1 g of
BSH with an estimated accuracy of about 90%. The final
boron concentration at 6 or 9 hours after the end of infusion
was within the 95% confidence intervals of the prediction for
5 out of 7 cases. For these cases, the prediction error from
low-dose infusion was 6.38%. There must be many causes for
the discrepancy between the test and final data. Many
factors, such as renal function, the volume of drip infusion,
the usage of diuretics, etc., can influence the clearance of
blood boron. These factors might have varied significantly in
the 2 cases in which the prediction errors were large.
Although it is impossible to control all physiological factors
in a clinical setting, 5 of the 7 cases studied here showed a
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good correlation between the test and final boron
pharmacokinetics. Further investigations should be
performed to determine the factors influencing the errors
seen in the present study. These factors should be controlled
in the same manner in future studies. Even though PGA
measurement appears to be reliable, reproducible and
sensitive, the measurement error of PGA should be clarified
in the future and the measurement method of boron
concentration needs to be improved to reduce errors.
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